Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases.

Abstract

There is no therapeutic agent approved in cutaneous mastocytosis and mast cell activation syndrome. We report the efficacy of hydroxychloroquine in four patients with cutaneous mastocytosis (n = 2) and mast cell activation syndrome (n = 2). We show that this molecule reduces the long-term survival of primary human mast cells, interferes with lysosome function and leads to the accumulation of non-functional tryptase in the mast cell granules. Furthermore, hydroxychloroquine decreases the production of pro-inflammatory mediators.

• Authors: Eric Espinosa, Salvatore Valitutti, Michel Laroche, Camille Laurent, Pol André Apoil, Olivier Hermine, Michel Lavit, Carle Paul, Cristina Bulai Livideanu
• Journal: Clinical immunology (Orlando, Fla.) (Clin Immunol) Vol. 194 Pg. 75-79 (09 2018) ISSN: 1521-7035 [Electronic] United States
• PMID: 30004016 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018. Published by Elsevier Inc.

Chemical References

• Inflammation Mediators
• Hydroxychloroquine

Topics

• Humans
• Hydroxychloroquine (therapeutic use)
• Inflammation Mediators (therapeutic use)
• Lysosomes (drug effects)
• Male
• Mast Cells (drug effects)
• Mastocytosis (drug therapy)
• Middle Aged